Actinium Pharmaceuticals, Inc.
ATNM· NYSE
ATNMActinium Pharmaceuticals, Inc.
Filed Aug 9, 2019 · 10-Q · 40 days after period end · 0001213900-19-015171
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Net Income | -$5.03M | -$4.86M | -$7.05M | -$6.62M |
| EPS Diluted | -$1.00 | -$0.04 | -$0.12 | -$0.15 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
ended Jun 30, 2019 · filed Aug 9, 2019 · 40 d after period end
